Collegium Pharma (NASDAQ: COLL) reported Q2 EPS of $0.23, $0.03 better than the analyst estimate of $0.20. Revenue for the quarter came in at $78.06 million versus the consensus estimate of $74.4 million.

“Collegium delivered strong financial results in the second quarter of 2020, which is a testament to the resilience and adaptability of our people and operations,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “We made progress towards achieving each of our key business objectives, while prioritizing the health and safety of our people, customers and communities. Xtampza ER revenue growth and the impact of the Nucynta acquisition generated meaningful cashflow from operations, enabling us to begin to pay down debt, and setting the stage for 2020 to be a financially transformative year for Collegium.”

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.